Table 3 Univariate and multivariate Cox regression analysis of OS.
Overall survival | |||
|---|---|---|---|
HR | 95% CI | p | |
Univariate analysis | |||
Sex (VS. female) | 0.739 | 0.376–1.453 | 0.381 |
Age (VS. ≥ 60 y) | 1.792 | 0.968–3.318 | 0.063 |
History of extracranial RT (VS. none) | 1.476 | 0.794–2.743 | 0.218 |
Pulmonary tumor (VS. extrapulmonary tumor) | 0.687 | 0.349–1.35 | 0.276 |
Chemotherapy (VS. none) | 0.762 | 0.427–1.36 | 0.358 |
Steroid use (VS. none) | 1.429 | 0.779–2.619 | 0.248 |
Metastases lesion ≤ 4 (VS. > 4) | 0.297 | 0.164–0.54 | 0.000 |
Pre-RT ALC | 0.397 | 0.198–0.798 | 0.009 |
ALC at 1 month post-RT | 0.417 | 0.193–0.901 | 0.026 |
ALC at 2 months post-RT | 0.342 | 0.128–0.908 | 0.031 |
G3-4 lymphopenia (VS. G0-2) at 1 month post-RT | 0.408 | 0.21–0.79 | 0.008 |
WBRT (VS. focal RT) | 1.686 | 0.941–3.019 | 0.079 |
Multivariate analysis | |||
Metastases lesion ≤ 4 (VS. > 4) | 0.216 | 0.095–0.493 | 0.000 |
G3-4 lymphopenia (VS. G0-2) at 1 month post-RT | 0.187 | 0.054–0.642 | 0.008 |
ALC at 2 months post-RT | 0.049 | 0.009–0.263 | 0.000 |
